{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:59:29Z","timestamp":1753441169403,"version":"3.40.5"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objectives<\/jats:title>\n<jats:p>Ceruloplasmin is an inhibitor of myeloperoxidase (MPO) activity that plays an important role in the pathophysiology of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This study aimed to evaluate the prognostic impact of serum level of ceruloplasmin at diagnosis in patients with anti-MPO antibody-positive AAV.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective monocentric study in Caen University Hospital involved all consecutive adult anti-MPO antibody-positive patients with microscopic polyangiitis or granulomatosis with polyangiitis, diagnosed between January 2010 and January 2022 with available serum sample at inclusion. Patients outcomes were analyzed from two subgroups constituted according to the median serum level of ceruloplasmin. The same analyses were then performed in anti-proteinase 3 (PR3) antibody-positive patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Within the 92 patients analyzed, 50 patients had anti-MPO antibodies with a median ceruloplasmin level of 0.44 [quartiles 1\u20133, 0.40\u20130.49] g\/L and a median Birmingham Vasculitis Activity Score of 19 [14\u201322]. After a median follow-up period of 40 [22\u201386] months, 13 (26%) patients had died: 10 (40%) in the low ceruloplasmin group and 3 (12%) in the high ceruloplasmin group (p = 0.03), with a significantly worse survival rate in the low ceruloplasmin group (p = 0.021). No significant differences in relapse rate or renal failure was observed between the two groups. The same analyses performed in the group of AAV patients with anti-PR3 antibody did not show any differences.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>In anti-MPO AAV patients, serum level of ceruloplasmin at diagnosis seems to be associated with a significant impact on survival.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0311678","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:25:47Z","timestamp":1728581147000},"page":"e0311678","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical impact of ceruloplasmin levels at ANCA-associated vasculitis diagnosis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6019-6292","authenticated-orcid":true,"given":"Louis","family":"Camboulive","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Grandhomme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Martin Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Khoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lobbedez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00ebl","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"de Boysson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"pone.0311678.ref001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0272-6386(95)90147-7","article-title":"Significance of myeloperoxidase in rapidly progressive glomerulonephritis","volume":"26","author":"T Saeki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"pone.0311678.ref002","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1016\/S0021-9258(19)69613-4","article-title":"Myeloperoxidase-catalyzed inactivation of alpha 1-protease inhibitor by human neutrophils","volume":"256","author":"RA Clark","year":"1981","journal-title":"J Biol Chem"},{"key":"pone.0311678.ref003","doi-asserted-by":"crossref","first-page":"1261151","DOI":"10.3389\/fimmu.2023.1261151","article-title":"The involvement of NETs in ANCA-associated vasculitis.","volume":"14","author":"S Shiratori-Aso","year":"2023","journal-title":"Front Immunol"},{"key":"pone.0311678.ref004","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1080\/10715760802566574","article-title":"Ceruloplasmin and myeloperoxidase in complex affect the enzymatic properties of each other","volume":"42","author":"AV Sokolov","year":"2008","journal-title":"Free Radic Res"},{"key":"pone.0311678.ref005","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3899\/jrheum.180591","article-title":"Clinical Effect of Alpha-1 Antitrypsin Deficiency in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Results from a French Retrospective Monocentric Cohort","volume":"46","author":"S Deshayes","year":"2019","journal-title":"J Rheumatol"},{"key":"pone.0311678.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"JC Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"pone.0311678.ref007","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"R Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"pone.0311678.ref008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/art.41986","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis","volume":"74","author":"JC Robson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"pone.0311678.ref009","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.41983","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis","volume":"74","author":"R Suppiah","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"pone.0311678.ref010","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3).","volume":"68","author":"C Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"article-title":"R: A language and environment for statistical computing. MSOR connections","year":"2014","author":"Team R.","key":"pone.0311678.ref011"},{"key":"pone.0311678.ref012","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis-clinical utility of using ANCA specificity to classify patients.","volume":"12","author":"D Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0311678.ref013","doi-asserted-by":"crossref","first-page":"e6083","DOI":"10.1097\/MD.0000000000006083","article-title":"Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity.","volume":"96","author":"R Solans-Laqu\u00e9","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"pone.0311678.ref014","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"S Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"pone.0311678.ref015","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"PA Lyons","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0311678.ref016","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00467-002-0969-0","article-title":"Ceruloplasmin levels in antineutrophil cytoplasmic antibody-positive patients","volume":"17","author":"E Baskin","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"pone.0311678.ref017","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ndt\/14.2.515b","article-title":"Ceruloplasmin in small vessel vasculitis.","volume":"14","author":"J Ara","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0311678.ref018","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5414\/CNP64475","article-title":"Vasculitis and infection: effects of immunosuppressive therapy.","volume":"64","author":"HM Lode","year":"2005","journal-title":"Clin Nephrol"},{"key":"pone.0311678.ref019","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"MA Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"pone.0311678.ref020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"DRW Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0311678.ref021","first-page":"256","volume":"7","author":"D S\u00f6derberg","year":"2016","journal-title":"Neutrophil Extracellular Traps in ANCA-Associated Vasculitis"},{"key":"pone.0311678.ref022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00281-013-0362-z","article-title":"Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis).","volume":"35","author":"B Korkmaz","year":"2013","journal-title":"Semin Immunopathol"},{"key":"pone.0311678.ref023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fimmu.2016.00227","article-title":"Peptidylarginine Deiminase Inhibitor Suppresses Neutrophil Extracellular Trap Formation and MPO-ANCA Production.","volume":"7","author":"Y Kusunoki","year":"2016","journal-title":"Front Immunol"},{"key":"pone.0311678.ref024","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1681\/ASN.2021081112","article-title":"Targeting Cathepsin C in PR3-ANCA Vasculitis","volume":"33","author":"U Jerke","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"pone.0311678.ref025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1681\/ASN.2019060618","article-title":"Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN","volume":"31","author":"M Antonelou","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"pone.0311678.ref026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00775-016-1335-1","article-title":"The Yin and Yang of Copper During Infection","volume":"21","author":"AN Besold","year":"2016","journal-title":"J Biol Inorg Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:25:57Z","timestamp":1728581157000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311678"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311678","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}